Preoperative treatment with radiochemotherapy for locally advanced gastroesophageal junction cancer and unresectable locally advanced gastric cancer

1. Rüschoff J. Adenocarcinoma of the GEJ: gastric or oesophageal cancer? Recent Results Cancer Res 2012; 196: 107-13.Search in Google Scholar

2. Ito H, Inoue H, Odaka N, Satodate H, Suzuki M, Mukai S, et al. Comparison of clinicopathological characteristics in the patients with cardiac cancer with or without esophagogastric junctional invasion: a single-center retrospective cohort study. Int J Surg Oncol 2013; 2013: 189459.10.1155/2013/189459355683923365732Search in Google Scholar

3. American Joint Committee on Cancer. AJCC cancer staging manual. 7th Edition. New York: Springer-Verlag; 2009.Search in Google Scholar

4. Buergy D, Lohr F, Baack T, Siebenlist K, Haneder S, Michaely H, et al.Radiotherapy for tumors of the stomach and gastroesophageal junction - a review of its role in multimodal therapy. Radiat Oncol 2012; 7: 192.10.1186/1748-717X-7-192355173323157945Search in Google Scholar

5. Lutz MP, Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D, et al. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer 2012; 48: 2941-53.10.1016/j.ejca.2012.07.02922921186Search in Google Scholar

6. Jeromen A, Oblak I, Anderluh F, Velenik V, Vidmar MS, Ratosa I. Results of postoperative radiochemotherapy of the patients with resectable gastroesophageal junction adenocarcinoma in Slovenia. Radiol Oncol 2012; 46: 337-45.10.2478/v10019-012-0049-4357289023412351Search in Google Scholar

7. D’Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004; 240: 808-16.10.1097/01.sla.0000143245.28656.15135648615492562Search in Google Scholar

8. Wayman J, Bennett MK, Raimes SA, Griffin SM. The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction. Br J Cancer 2002; 86: 1223-9.10.1038/sj.bjc.6600252237532811953876Search in Google Scholar

9. Oblak I, Vidmar SM, Anderluh F, Velenik V, Jeromen A, Hadzic JB. Capecitabine in adjuvant radiochemotherapy for gastric adenocarcinoma. Radiol Oncol 2015; 49(2): 163-172.; 48: 189-96.10.2478/raon-2013-0065407803824991209Search in Google Scholar

10. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.10.1056/NEJMoa05553116822992Search in Google Scholar

11. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-30.10.1056/NEJMoa01018711547741Search in Google Scholar

12. Oblak I, Velenik V, Anderluh F, Mozina B, Ocvirk J. The correlation between the levels of tissue inhibitor of metalloproteinases 1 in plasma and tumour response and survival after preoperative radiochemotherapy in patients with rectal cancer. Radiol Oncol 2013; 47: 138-44.10.2478/raon-2013-0028369108123801910Search in Google Scholar

13. Van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074-84.10.1056/NEJMoa111208822646630Search in Google Scholar

14. Ychou M, Boige V, Pignon J-P, Conroy T, Bouché O, Lebreton G, et al.Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011; 29: 1715-21.10.1200/JCO.2010.33.059721444866Search in Google Scholar

15. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer H-J, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27: 851-6.10.1200/JCO.2008.17.050619139439Search in Google Scholar

16. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004; 22: 2774-80.10.1200/JCO.2004.01.01515254045Search in Google Scholar

17. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005; 23: 1237-44.10.1200/JCO.2005.01.30515718321Search in Google Scholar

18. Rivera F, Galán M, Tabernero J, Cervantes A, Vega-Villegas ME, Gallego J, et al. Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma. Int J Radiat Oncol Biol Phys 2009; 75: 1430-6.10.1016/j.ijrobp.2008.12.08719540072Search in Google Scholar

19. Oblak I, Anderluh F, Velenik V, Jeromen A, Ratoša I, Skoblar Vidmar M. Preoperative radiochemotherapy in patients with locoregionally inresectable gastric cancer. [Abstract]. Ann Oncol 2011; 22(Suppl 5): V37.Search in Google Scholar

20. Díaz-González JA, Rodríguez J, Hernández-Lizoain JL, Ciérvide R, Gaztañaga M, San Miguel I, et al. Patterns of response after preoperative treatment in gastric cancer. Int J Radiat Oncol Biol Phys 2011; 80: 698-704.10.1016/j.ijrobp.2010.02.05420656414Search in Google Scholar

21. Pepek JM, Chino JP, Willett CG, Palta M, Blazer Iii DG, Tyler DS, et al. Preoperative chemoradiotherapy for locally advanced gastric cancer. Radiat Oncol 2013; 8: 6.10.1186/1748-717X-8-6355275423286735Search in Google Scholar

22. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PWT, Crane CH, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 2006; 24: 3953-8.10.1200/JCO.2006.06.484016921048Search in Google Scholar

23. Lowy AM, Feig BW, Janjan N, Rich TA, Pisters PW, Ajani JA, et al. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol 2001; 8: 519-24.10.1007/s10434-001-0519-111456051Search in Google Scholar

24. McCloskey SA, Yang GY. Benefits and challenges of radiation therapy in gastric cancer: techniques for improving outcomes. Gastrointest Cancer Res 2009; 3: 15-9.Search in Google Scholar

25. Koukourakis G V. Evidence based radiation therapy for locally advanced resectable and unresectable gastric cancer. World J Gastrointest Oncol 2011; 3: 131-6.10.4251/wjgo.v3.i9.131Search in Google Scholar

26. Valenti V, Hernandez-Lizoaín JL, Beorlegui MC, Diaz-Gozalez JA, Regueira FM, Rodriguez JJ, et al. Morbidity, mortality, and pathological response in patients with gastric cancer preoperatively treated with chemotherapy or chemoradiotherapy. J Surg Oncol 2011; 104: 124-9.10.1002/jso.21947Search in Google Scholar

27. Leong T, Smithers M, Michael M, Gebski V, Boussioutas A, Miller D, et al. TOPGEAR: an international randomized phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer (AGITG/TROG/EORTC/NCIC CTG). [Abstract]. 2012 ASCO Annual Meeting. J Clin Oncol 2012; 30(Suppl). Abstr. No TPS4141. Available from: http://meetinglibrary.asco.org/content/99024-114. Accessed on 5th April, 2014.Search in Google Scholar

28. Tannock IF. Treatment of cancer with radiation and drugs. J Clin Oncol 1996; 14: 3156-74.10.1200/JCO.1996.14.12.3156Search in Google Scholar

29. Hennequin C, Favaudon V. Biological basis for chemo-radiotherapy interactions. Eur J Cancer 2002; 38: 223-30.10.1016/S0959-8049(01)00360-4Search in Google Scholar

30. Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm- -general principles. Nat Clin Pract Oncol 2007; 4: 86-100.10.1038/ncponc0714Search in Google Scholar

31. Moertel CG, Childs DS, Reitemeier RJ, Colby MY, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969; 2(7626): 865-7.10.1016/S0140-6736(69)92326-5Search in Google Scholar

32. Yoshimizu N, Saikawa Y, Kubota T, Akiba Y, Yoshida M, Otani Y, et al. Complete response of a highly advanced gastric carcinoma to preoperative chemoradiotherapy with S-1 and low-dose cisplatin. Gastric Cancer 2003; 6: 185-90.10.1007/s10120-003-0239-214520533Search in Google Scholar

33. Takahashi T, Saikawa Y, Kubota T, Akiba Y, Shigematsu N, Yoshida M, et al. Histological complete response in a case of advanced gastric cancer treated by chemotherapy with S-1 plus low-dose cisplatin and radiation. Jpn J Clin Oncol 2003; 33: 584-8.10.1093/jjco/hyg11014711984Search in Google Scholar

34. Shigeoka H, Imamoto H, Nishimura Y, Shimono T, Furukawa H, Imamura H, et al. Complete response to preoperative chemoradiotherapy in highly advanced gastric adenocarcinoma. World J Gastrointest Oncol 2010; 2: 282-6.10.4251/wjgo.v2.i6.282299918821160641Search in Google Scholar

35. Roth AD, Allal AS, Bründler M-A, de Peyer R, Mermillod B, Morel P, et al. Neoadjuvant radiochemotherapy for locally advanced gastric cancer: a phase I-II study. Ann Oncol 2003; 14: 110-5.10.1093/annonc/mdg02312488302Search in Google Scholar

36. Allal AS, Zwahlen D, Bründler M-A, de Peyer R, Morel P, Huber O, et al. Neoadjuvant radiochemotherapy for locally advanced gastric cancer: longterm results of a phase I trial. Int J Radiat Oncol Biol Phys 2005; 63: 1286-9.10.1016/j.ijrobp.2005.05.033Search in Google Scholar

37. Klautke G, Foitzik T, Ludwig K, Ketterer P, Klar E, Fietkau R. Neoadjuvant radiochemotherapy in locally advanced gastric carcinoma. Strahlenther Onkol 2004; 180: 695-700.10.1007/s00066-004-9194-zSearch in Google Scholar

38. Schein PS, Smith FP, Woolley P V, Ahlgren JD. Current management of advanced and locally unresectable gastric carcinoma. Cancer 1982; 50(11 Suppl): 2590-6.Search in Google Scholar

39. Hazard L, O’Connor J, Scaife C. Role of radiation therapy in gastric adenocarcinoma. World J Gastroenterol 2006; 12: 1511-20.10.3748/wjg.v12.i10.1511Search in Google Scholar

40. Henning GT, Schild SE, Stafford SL, Donohue JH, Burch PA, Haddock MG, et al. Results of irradiation or chemoirradiation following resection of gastric adenocarcinoma. Int J Radiat Oncol Biol Phys 2000; 46: 589-98.10.1016/S0360-3016(99)00446-0Search in Google Scholar

41. National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/About.html. Accessed 2nd June, 2013.Search in Google Scholar

42. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.10.1080/01621459.1958.10501452Search in Google Scholar

43. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard S V, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977; 35: 1-39.10.1038/bjc.1977.1Search in Google Scholar

44. Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376(9742): 687-97.10.1016/S0140-6736(10)61121-XSearch in Google Scholar

45. Burmeister BH, Thomas JM, Burmeister EA, Walpole ET, Harvey JA, Thomson DB, et al. Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. Eur J Cancer 2011; 47: 354-60. 10.1016/j.ejca.2010.09.00921084184Search in Google Scholar